Impact News +++ Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with... (GlobeNewswire EN) +++ AXSOME Aktie +3,23%

EIGER BIOPHARMACEUTICALS Aktie

 >EIGER BIO Aktienkurs 
7.45 EUR    (Tradegate)
Ask: 7.55 EUR / 396 Stück
Bid: 7.35 EUR / 409 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
>EIGER BIO Performance
1 Woche: +2,0%
1 Monat: -0,6%
3 Monate: -17,1%
6 Monate: -27,9%
1 Jahr: -34,9%
laufendes Jahr: -43,6%
>EIGER BIOPHARMACEUTICALS Aktie
Name:  EIGER BIOPHARM. DL -,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US28249U1051 / A2AF9X
Symbol/ Ticker:  72C1 (Frankfurt) / EIGR (NASDAQ)
Kürzel:  FRA:72C1, 72C1.F, 72C1:GR, NASDAQ:EIGR
Index:  -
Webseite:  http://www.eigerbio.com/
Marktkapitalisierung:  238.88 Mio. EUR
Umsatz:  -
EBITDA:  -50.62 Mio. EUR
Gewinn je Aktie:  -2.023 EUR
Schulden:  27.11 Mio. EUR
Liquide Mittel:  104.76 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 3 / -
Gewinnm./ Eigenkapitalr.:  - / -76.75%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  EIGER BIOPHARMACEUTICALS, EIGER BIOPHARMACEUTICAL, EIGER BIOPHARMA, EIGER BIO
Letzte Datenerhebung:  30.11.20
>EIGER BIO Eigentümer
Aktien: 32.53 Mio. St.
f.h. Aktien: 26.05 Mio. St.
Insider Eigner: 1.27%
Instit. Eigner: 74.54%
Leerverk. Aktien: 4.50%
>EIGER BIO Peer Group

 
25.11.20 - 14:45
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
 
PALO ALTO, Calif. , Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare......
23.11.20 - 16:55
FDA Approves Eiger Biopharma′s Progeria Treatment: What Investors Should Know (Benzinga)
 
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-deficient progeroid laminopathies. read more...
23.11.20 - 15:01
Eiger Bio (EIGR) rises 8% on sale of priority review voucher for $95M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.11.20 - 14:49
Eiger Bio rises 8% on sale of priority review voucher for $95M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.11.20 - 14:06
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million (PR Newswire)
 
PALO ALTO, Calif. , Nov. 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare......
21.11.20 - 04:57
FDA OK′s Eiger BioPharma′s Hutchinson-Gilford treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.11.20 - 00:00
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
 
PALO ALTO, Calif. , Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare......
17.11.20 - 14:06
Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience™ 2020 (PR Newswire)
 
PALO ALTO, Calif. , Nov. 17, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and......
16.11.20 - 22:12
Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience™ 2020 (PR Newswire)
 
PALO ALTO, Calif. , Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and......
02.11.20 - 22:36
Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience™ 2020 (PR Newswire)
 
PALO ALTO, Calif. , Nov. 2, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious......
02.11.20 - 07:15
Will Eiger′s Zokinvy Make History To Become First-ever Progeria Treatment? (RTTNews)
 
Shares of Eiger BioPharmaceuticals Inc. (EIGR) are down 44 percent from their 52-week high of $15.82, recorded on December 26, 2019, and trade around $8.00....
16.10.20 - 14:22
Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.10.20 - 08:46
SNY/TBIO Move COVID-19 Vaccine Into Clinic, AVXL′s PDD Study Promising, EIGR On Watch (RTTNews)
 
Today's Daily Dose brings you news about Eiger BioPharma's COVID-19 ILIAD study results, disappointing results of Servier/Galapagos' knee osteoarthritis drug trial, Anavex Life's Parkinson's disease dementia trial, the progress in Sanofi/Transla...
15.10.20 - 21:31
Why Eiger BioPharmaceuticals Stock Skyrocketed Today (Fool)
 
Investors were excited about the company's positive results from a COVID-19 clinical study...
15.10.20 - 14:40
Eiger Biopharma +17% on positive Lambda data in COVID-19 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.10.20 - 14:19
Eiger Bio treatment shows lowered viral load for Covid-19 patients (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Zitat des Tages: Katz aus dem Haus, rührt sich die Maus. - Sprichwort Deutschland
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!